These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 30803706)

  • 1. Mineralocorticoid Antagonism and Vascular Function in Early Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Trial.
    Nowak KL; Gitomer B; Farmer-Bailey H; Wang W; Malaczewski M; Klawitter J; You Z; George D; Patel N; Jovanovich A; Chonchol M
    Am J Kidney Dis; 2019 Aug; 74(2):213-223. PubMed ID: 30803706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular Dysfunction, Oxidative Stress, and Inflammation in Autosomal Dominant Polycystic Kidney Disease.
    Nowak KL; Wang W; Farmer-Bailey H; Gitomer B; Malaczewski M; Klawitter J; Jovanovich A; Chonchol M
    Clin J Am Soc Nephrol; 2018 Oct; 13(10):1493-1501. PubMed ID: 30228110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults with ADPKD: A Randomized Controlled Trial.
    Nowak KL; Farmer-Bailey H; Wang W; You Z; Steele C; Cadnapaphornchai MA; Klawitter J; Patel N; George D; Jovanovich A; Soranno DE; Gitomer B; Chonchol M
    Clin J Am Soc Nephrol; 2022 Feb; 17(2):240-250. PubMed ID: 34907021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease.
    Nowak KL; Farmer H; Cadnapaphornchai MA; Gitomer B; Chonchol M
    Nephrol Dial Transplant; 2017 Feb; 32(2):342-347. PubMed ID: 28186577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin blockade in late autosomal dominant polycystic kidney disease.
    Torres VE; Abebe KZ; Chapman AB; Schrier RW; Braun WE; Steinman TI; Winklhofer FT; Brosnahan G; Czarnecki PG; Hogan MC; Miskulin DC; Rahbari-Oskoui FF; Grantham JJ; Harris PC; Flessner MF; Moore CG; Perrone RD;
    N Engl J Med; 2014 Dec; 371(24):2267-76. PubMed ID: 25399731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study.
    Brosnahan GM; Wang W; Gitomer B; Struemph T; George D; You Z; Nowak KL; Klawitter J; Chonchol MB
    Am J Kidney Dis; 2022 Apr; 79(4):518-526. PubMed ID: 34391872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): study protocol for a randomized controlled pilot trial.
    Ng KP; Jain P; Heer G; Redman V; Chagoury OL; Dowswell G; Greenfield S; Freemantle N; Townend JN; Gill PS; McManus RJ; Ferro CJ
    Trials; 2014 May; 15():158. PubMed ID: 24886272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute effect of mineralocorticoid receptor antagonism on vascular function in healthy older adults.
    Hwang MH; Yoo JK; Luttrell M; Kim HK; Meade TH; English M; Talcott S; Jaffe IZ; Christou DD
    Exp Gerontol; 2016 Jan; 73():86-94. PubMed ID: 26639352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of spironolactone for 1 yr on endothelial function and vascular inflammation biomarkers in renal transplant recipients.
    Mortensen LA; Bistrup C; Stubbe J; Carlström M; Checa A; Wheelock CE; Palarasah Y; Bladbjerg EM; Thiesson HC; Jensen BL
    Am J Physiol Renal Physiol; 2019 Sep; 317(3):F529-F539. PubMed ID: 31166706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4--a randomized controlled study.
    Boesby L; Elung-Jensen T; Strandgaard S; Kamper AL
    PLoS One; 2013; 8(5):e64549. PubMed ID: 23704994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineralocorticoid Receptor Antagonism Prevents Aortic Plaque Progression and Reduces Left Ventricular Mass and Fibrosis in Patients With Type 2 Diabetes and Chronic Kidney Disease: The MAGMA Trial.
    Rajagopalan S; Dobre M; Dazard JE; Vergara-Martel A; Connelly K; Farkouh ME; Gaztanaga J; Conger H; Dever A; Razavi-Nematollahi L; Fares A; Pereira G; Edwards-Glenn J; Cameron M; Cameron C; Al-Kindi S; Brook RD; Pitt B; Weir M
    Circulation; 2024 Aug; 150(9):663-676. PubMed ID: 39129649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial.
    Gansevoort RT; Hariri A; Minini P; Ahn C; Chapman AB; Horie S; Knebelmann B; Mrug M; Ong ACM; Pei YPC; Torres VE; Modur V; Antonshchuk I; Perrone RD
    Am J Kidney Dis; 2023 May; 81(5):517-527.e1. PubMed ID: 36535535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects.
    Garg R; Kneen L; Williams GH; Adler GK
    Diabetes Obes Metab; 2014 Mar; 16(3):268-72. PubMed ID: 24125483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease: A Randomized, Open-Label Trial.
    Edwards NC; Price AM; Mehta S; Hiemstra TF; Kaur A; Greasley PJ; Webb DJ; Dhaun N; MacIntyre IM; Farrah T; Melville V; Herrey AS; Slinn G; Wale R; Ives N; Wheeler DC; Wilkinson I; Steeds RP; Ferro CJ; Townend JN
    Clin J Am Soc Nephrol; 2021 Oct; 16(10):1491-1501. PubMed ID: 34462286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yinang formulation versus placebo granules as a treatment for chronic kidney disease stages III-IV in patients with autosomal dominant polycystic kidney disease: study protocol for a double-blind placebo-controlled randomized clinical trial.
    Gan J; Wu Y; Gong X; Ma Y; Yu S; Gao J
    Trials; 2019 Aug; 20(1):481. PubMed ID: 31391092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.
    Meijer E; Visser FW; van Aerts RMM; Blijdorp CJ; Casteleijn NF; D'Agnolo HMA; Dekker SEI; Drenth JPH; de Fijter JW; van Gastel MDA; Gevers TJ; Lantinga MA; Losekoot M; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Wetzels JF; Zietse R; Gansevoort RT;
    JAMA; 2018 Nov; 320(19):2010-2019. PubMed ID: 30422235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exercise capacity in polycystic kidney disease.
    Reinecke NL; Cunha TM; Heilberg IP; Higa EM; Nishiura JL; Neder JA; Almeida WS; Schor N
    Am J Kidney Dis; 2014 Aug; 64(2):239-46. PubMed ID: 24787761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results and lessons from the Spironolactone To Prevent Cardiovascular Events in Early Stage Chronic Kidney Disease (STOP-CKD) randomised controlled trial.
    Ng KP; Jain P; Gill PS; Heer G; Townend JN; Freemantle N; Greenfield S; McManus RJ; Ferro CJ
    BMJ Open; 2016 Feb; 6(2):e010519. PubMed ID: 26916697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study of the effect of spironolactone therapy on exercise capacity and endothelial dysfunction in pulmonary arterial hypertension: study protocol for a randomized controlled trial.
    Elinoff JM; Rame JE; Forfia PR; Hall MK; Sun J; Gharib AM; Abd-Elmoniem K; Graninger G; Harper B; Danner RL; Solomon MA
    Trials; 2013 Apr; 14():91. PubMed ID: 23547564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.